Significance of serum Myostatin in hemodialysis patients

Autor: Pasquale Esposito, Yuri Battaglia, Edoardo La Porta, Maria Antonietta Grignano, Elena Caramella, Alessando Avella, Sabrina Peressini, Nicodemo Sessa, Riccardo Albertini, Giuseppe Di Natali, Claudio Lisi, Marilena Gregorini, Teresa Rampino
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Zdroj: BMC Nephrology, Vol 20, Iss 1, Pp 1-8 (2019)
Druh dokumentu: article
ISSN: 1471-2369
DOI: 10.1186/s12882-019-1647-9
Popis: Abstract Background Malnutrition and muscle wasting are common in haemodialysis (HD) patients. Their pathogenesis is complex and involves many molecules including Myostatin (Mstn), which acts as a negative regulator of skeletal muscle. The characterisation of Mstn as a biomarker of malnutrition could be useful in the prevention and management of this condition. Previous studies have reported no conclusive results on the actual relationship between serum Mstn and wasting and malnutrition. So, in this study, we evaluated Mstn profile in a cohort of regular HD patients. Methods We performed a cross-sectional study, enrolling 37 patients undergoing bicarbonate-HD (BHD) or haemodiafiltration (HDF) at least for six months. 20 sex-matched healthy subjects comprised the control group. Mstn serum levels were evaluated by ELISA before and after HD. We collected clinical and biochemical data, evaluated insulin resistance, body composition, malnutrition [by Malnutrition Inflammation Score (MIS)] and tested muscle function (by hand-grip strength, six-minute walking test and a questionnaire on fatigue). Results Mstn levels were not significantly different between HD patients and controls (4.7 ± 2.8 vs 4.5 ± 1.3 ng/ml). In addition, while a decrease in Mstn was observed after HD treatment, there were no differences between BHD and HDF. In whole group of HD patients Mstn was positively correlated with muscle mass (r = 0.82, p
Databáze: Directory of Open Access Journals